Progyny has approved a share repurchase program to repurchase up to $100M of its common stock. This follows the program that was previously announced on February 29. The program will be funded through available cash balances. The program may be suspended or discontinued at any time.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PGNY:
- Progyny price target lowered to $37 from $46 at Truist
- Progyny price target lowered to $41 from $51 at JPMorgan
- Progyny, Inc. to Present at BofA Securities 2024 Healthcare Conference and Leerink Partners Healthcare Crossroads Conference 2024
- Progyny price target lowered to $30 from $48 at Barclays
- Progyny price target lowered to $37 from $46 at BofA